Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Sanofi
Deal Size : $740.0 million
Deal Type : Collaboration
Belharra & Sanofi Partner to Discover New Small Molecules for Immunological Diseases
Details : The collaboration will leverage Belharra’s proprietary, non-covalent chemoproteomics platform to identify and advance small molecules against Sanofi-designated immunology targets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $40.0 million
June 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Sanofi
Deal Size : $740.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Genentech
Deal Size : $2,080.0 million
Deal Type : Collaboration
Details : Belharra will be responsible for discovery and early preclinical development of small molecules against Genentech’s designated targets, while Genentech will be responsible for late preclinical, clinical, and regulatory development, and commercializatio...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $80.0 million
January 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Genentech
Deal Size : $2,080.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Undisclosed
Sponsor : Versant Ventures
Deal Size : $50.0 million
Deal Type : Series A Financing
Belharra Therapeutics Debuts With $130 Million in Funding
Details : Belharra’s integrated chemoproteomic-based drug discovery engine addresses the limitations of traditional screening approaches through a proprietary library of photoaffinity-based chemical probes that explore protein-ligand interactions in the native e...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Sponsor : Versant Ventures
Deal Size : $50.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?